rcca-header
Clinical Trials

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Head and Neck
Phase
Division (Location)
Hackensack, NJ
Study ID
NCT#
Brief Description
PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.